Members

  First name: Gilles
  Last name: Peytavin
  Function: Pharmacologist - Researcher
  Position: Hospital practitioner
  Email: gilles.peytavin
._
_.
bch.aphp.fr

Research interest



Exhaustive list of publications

2022


Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F, DSG
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
The Lancet. Infectious Diseases 2022, 22, 209-221.

Ghosn J, Assoumou L, Lascoux-Combe C, Peytavin G, Amat K, Gabassi A, Le MP, Nzalakanda R, Valin N, Landman R, Chaix ML, Delaugerre C
HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection.
The Journal of Infectious Diseases 2022, 225, 116-120.

Le Hingrat Q, Collin G, Damond F, Peytavin G, Lebourgeois S, Ghosn J, Bachelard A, Ferré VM, Matheron S, Descamps D, Charpentier C
In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions.
The Journal of Antimicrobial Chemotherapy 2022, 77, 409-412.

Lê MP, Ferré VM, Mazy F, Bourgeois-Moine A, Damond F, Matheron S, Descamps D, Ghosn J, Peytavin G
Bictegravir pharmacokinetics in a late-presenting HIV-1-infected pregnant woman: a case report.
The Journal of Antimicrobial Chemotherapy 2022, 77, 851-853.

Lingas G, Néant N, Gaymard A, Belhadi D, Peytavin G, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Wallet F, Gagneux-Brunon A, Mentré F, Ader F, Burdet C, Guedj J, Bouscambert-Duchamp M
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.
The Journal of Antimicrobial Chemotherapy 2022, 77, 1404-1412.

Le Hingrat Q, Collin G, Bachelard A, Ghosn J, Chalal S, Pacanowski J, Peytavin G, Weinheimer S, Marsolais C, Damond F, Matheron S, Charpentier C, Descamps D, atACH2c
Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates.
AIDS (London, England) 2022

Pourcher V, Capeau J, Dudoit Y, Boccara F, Soulié C, Ndoadoumgue AL, Charlotte F, Fellahi S, Bastard JP, Béréziat V, Lagathu C, Marcelin AG, Peytavin G, Boutron-Ruault MC, Tubbax C, D'Avout D'Auerstaedt A, Valantin MA, Schneider L, Costagliola D, Katlama C, Assoumou L, Pourcher G
Comparison of HIV-infected and non-infected patients undergoing bariatric surgery: the ObeVIH study.
Journal of Acquired Immune Deficiency Syndromes (1999) 2022

2021


Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure FX, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-Jehl R, Bouiller K, Navellou JC, Tolsma V, Cabié A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix JP, Makinson A, Martin-Blondel G, Bouadma L, Botelho-Nevers E, Gagneux-Brunon A, Epaulard O, Piroth L, Wallet F, Richard JC, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Lê MP, Peytavin G, Hites M, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F, Dsg
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2021, S1198-743X(21)00259-7.

Louchet M, Peytavin G, Didelot H, Lê M, Bourgeois-Moine A, Carbillon L, Luton D, Matheron I, Rigonnot L, Mandelbrot L
Frequency of differential placental transfer to twins of maternal antiretroviral medications.
European Journal of Obstetrics, Gynecology, and Reproductive Biology 2021, 256, 405-411.

Meybeck A, Tetart M, Baclet V, Alcaraz I, Blondiaux N, Peytavin G, Veyziris N, Robineau O, Senneville E
A disseminated Mycobacterium marinum infection in a renal transplant HIV-infected patient successfully treated with a bedaquiline-containing antimycobacterial treatment: a case report.
International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2021

Klement-Frutos E, Burrel S, Peytavin G, Marot S, Lê MP, Godefroy N, Calvez V, Marcelin AG, Caumes E, Pourcher V, Boutolleau D
Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.
The Journal of Infection 2021, 82, 159-198.

Lê MP, Peiffer-Smadja N, Guedj J, Neant N, Mentré F, Ader F, Yazdanpanah Y, Peytavin G, C21DFSC
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response.
The Journal of Antimicrobial Chemotherapy 2021, 76, 277-279.

Palich R, Allavena C, Peytavin G, Soulie C, Tubiana R, Weiss L, Montoya Ferrer A, Duvivier C, Bouchaud O, Bottero J, Durand A, Lê MP, Marcelin AG, Dudoit Y, Assoumou L, Katlama C, EQsg
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
The Journal of Antimicrobial Chemotherapy 2021, 76, 477-481.

Force G, Ghout I, Ropers J, Carcelain G, Marigot-Outtandy D, Hahn V, Darchy N, Defferriere H, Bouaziz-Amar E, Carlier R, Dorgham K, Callebert J, Peytavin G, Delaugerre C, de Truchis P, NSG
Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study.
The Journal of Antimicrobial Chemotherapy 2021, 76, 743-752.

Palich R, Abdi B, Wirden M, Lourida G, Tubiana R, Faycal A, Valantin MA, Schneider L, Seang S, Agher R, Simon A, Soulie C, Le MP, Peytavin G, Calvez V, Marcelin AG, Katlama C
Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.
The Journal of Antimicrobial Chemotherapy 2021, 76, 1893-1897.

Bachelard A, Isernia V, Vallois D, Le Gac S, Chalal L, Landman R, Damond F, Descamps D, Yazdanpanah Y, Peytavin G, Ghosn J
Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2484-2485.

Lê MP, Pencolé L, Peytavin G, Bouchet-Crivat F, Mandelbrot L
Placental transfer of doravirine, a recent HIV-1 NNRTI in the ex vivo human cotyledon perfusion model.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2364-2367.

Chas J, Bauer R, Larabi IA, Peytavin G, Roux P, Cua E, Cotte L, Pasquet A, Capitant C, Meyer L, Raffi F, Spire B, Pialoux G, Molina JM, Alvarez JC
Evaluation of Drug Abuse by Hair Analysis and Self-Reported Use Among MSM Under PrEP: Results From a French Substudy of the ANRS-IPERGAY Trial.
Journal of Acquired Immune Deficiency Syndromes (1999) 2021, 86, 552-561.

2020


Louchet M, Sibiude J, Peytavin G, Picone O, Tréluyer JM, Mandelbrot L
Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019.
American journal of obstetrics & gynecology MFM 2020, 2, 100159.

Venisse N, Peytavin G, Bouchet S, Gagnieu MC, Garraffo R, Guilhaumou R, Solas C
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.
Antiviral Research 2020, 181, 104866.

André-Garnier E, Hingrat QL, Marcelin AG, Reliquet V, Malet I, Leducq V, Rodallec A, Peytavin G, Ferré V, Charpentier C, Raffi F
Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
International Journal of Antimicrobial Agents 2020, 106039.

San C, Lê MP, Matheron S, Mourvillier B, Caseris M, Timsit JF, Wolff M, Yazdanpanah Y, Descamps D, Peytavin G
Management of oral antiretroviral administration in patients with swallowing disorders or with an enteral feeding tube.
Medecine Et Maladies Infectieuses 2020, 50, 537-544.

Brice J, Sylla M, Desire N, Sayon S, Telly F, Bocar-Fofana D, Murphy R, Peytavin G, Diallo S, Nastouli E, Calvez V, Marcelin AG, Maiga AI, Lambert-Niclot S
Characterization of drug resistance and the defective HIV reservoir in virally suppressed vertically infected children in Mali.
The Journal of Antimicrobial Chemotherapy 2020, 75, 1272-1279.

Jary A, Marcelin AG, Charpentier C, Wirden M, Lê MP, Peytavin G, Descamps D, Calvez V
M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.
The Journal of Antimicrobial Chemotherapy 2020, 75, 1290-1293.

Charpentier C, Peytavin G, Raffi F, Burdet C, Landman R, Lê MP, Katlama C, Collin G, Benalycherif A, Cabie A, Mentré F, Yazdanpanah Y, Descamps D, Joly V
Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
The Journal of Antimicrobial Chemotherapy 2020, 75, 1611-1617.

Soulie C, Assoumou L, Abdi B, Sayon S, Nguyen T, Valantin MA, Beniguel L, Ferre V, Alloui C, Montes B, Avettand-Fenoel V, Delaugerre C, Descamps D, Martinez E, Reynes J, Peytavin G, Costagliola D, Katlama C, Calvez V, Marcelin AG, A1Esg
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
The Journal of Antimicrobial Chemotherapy 2020, 75, 1943-1949.

Boyd A, Miailhes P, Chas J, Valantin MA, Yazdanpanah Y, Rosenthal E, Chevaliez S, Piroth L, Rougier H, Peytavin G, Pialoux G, Girard PM, Lacombe K
Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.
The Journal of Antimicrobial Chemotherapy 2020, 75, 1961-1968.

Alain S, Feghoul L, Girault S, Lepiller Q, Frobert E, Michonneau D, Berceanu A, Ducastelle-Lepretre S, Tilloy V, Guerin E, Le Goff J, Peytavin G, Hantz S
Letermovir breakthroughs during the French Named Patient Programme: interest of monitoring blood concentration in clinical practice.
The Journal of Antimicrobial Chemotherapy 2020, 75, 2253-2257.

Lê MP, Peiffer-Smadja N, Guedj J, Néant N, Mentré F, Ader F, Yazdanpanah Y, Peytavin G
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
The Journal of Antimicrobial Chemotherapy 2020, 75, 2376-2380.

Kauv J, Lê MP, Veyrier M, Le Hingrat Q, Visseaux B, Massias L, Chauveheid MP, Descamps D, Ghosn J, Peytavin G
Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report.
The Journal of Antimicrobial Chemotherapy 2020, 75, 2706-2707.

Lê MP, Jaquet P, Patrier J, Wicky PH, Le Hingrat Q, Veyrier M, Kauv J, Sonneville R, Visseaux B, Laouénan C, Bouadma L, Descamps D, de Montmollin E, Peytavin G, Timsit JF
Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients.
The Journal of Antimicrobial Chemotherapy 2020, 75, 2657-2660.

Palich R, Wirden M, Peytavin G, Lê MP, Seang S, Abdi B, Schneider L, Tubiana R, Valantin MA, Paccoud O, Soulié C, Calvez V, Katlama C, Marcelin AG
Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations.
The Journal of Antimicrobial Chemotherapy 2020, 75, 2981-2985.

Katlama C, Assoumou L, Valantin MA, Soulié C, Martinez E, Béniguel L, Bouchaud O, Raffi F, Molina JM, Fellahi S, Peytavin G, Marcelin AG, Kolta S, Capeau J, Gibowski S, Cardon F, Reynes J, Costagliola D
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response.
The Journal of Antimicrobial Chemotherapy 2020, 75, 3699-3700.

Tebano G, Soulié C, Schneider L, Blanc C, Agher R, Seang S, Valantin MA, Palich R, Tubiana R, Peytavin G, Marcelin AG, Assoumou L, Katlama C
Long-term follow-up of HIV-infected patients on dolutegravir monotherapy.
The Journal of Antimicrobial Chemotherapy 2020, 75, 675-680.

Pencolé L, Lê MP, Bouchet-Crivat F, Duro D, Peytavin G, Mandelbrot L
Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model.
AIDS (London, England) 2020, 34, 2145-2149.

Néant N, Lê MP, Bouazza N, Gattacceca F, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Solas C
Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients.
British Journal of Clinical Pharmacology 2020, 86, 2404-2413.

Lê MP, Le Hingrat Q, Jaquet P, Wicky PH, Bunel V, Massias L, Visseaux B, Messika J, Descamps D, Mal H, Timsit JF, Peytavin G
Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19.
Antimicrobial Agents and Chemotherapy 2020, 64,

Lê MP, Le Beller C, Le Hingrat Q, Jaquet P, Wicky PH, Bunel V, Massias L, Visseaux B, Messika J, Descamps D, Mal H, Timsit JF, Peytavin G
Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity".
Antimicrobial Agents and Chemotherapy 2020, 64,

Faure Bardon V, Peytavin G, Lê MP, Guilleminot T, Elefant E, Stirnemann J, Leruez-Ville M, Ville Y, Spradley FT
Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection.
PLOS ONE 2020, 15, e0232140.

Jaspard M, Butel N, El Helali N, Marigot-Outtandy D, Guillot H, Peytavin G, Veziris N, Bodaghi B, Flandre P, Petitjean G, Caumes E, Pourcher V
Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France.
Emerging Infectious Diseases 2020, 26, 1792-1800.

Dang E, Sayagh F, Lê MP, Neuville M, Sinnah F, Timsit JF, Peytavin G
Plasma pharmacokinetics of bedaquiline administered by nasogastric tube in an intensive care unit.
The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union Against Tuberculosis and Lung Disease 2020, 24, 110-112.

Lévy Y, Lelièvre JD, Assoumou L, Aznar E, Pulido F, Tambussi G, Crespo M, Meybeck A, Molina JM, Delaugerre C, Izopet J, Peytavin G, Cardon F, Diallo A, Lancar R, Béniguel L, Costagliola D
Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial.
Annals of Internal Medicine 2020, 172, 297.

2019


Lê MP, Valantin M, Assoumou L, Soulie C, Le Mestre S, Weiss L, Yazdanpanah Y, Molina J, Bouchaud O, Raffi F, Reynes J, Calvez V, Marcelin A, Costagliola D, Katlama C, Peytavin G, AEsg, Duvivier C, Goujard C, Jeantils V, Salmon D, Simon A, Colin de Verdière N, Morlat P, Poizot‐Martin I, Allavena C, Naqvi A, Bernard L, Chidiac C, Hamdoud K
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS ‐163 ETRAL Study.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2019, 39, 514-520.

May F, Peytavin G, Fourati S, Pressiat C, Carteaux G, Razazi K, Mekontso Dessap A, de Prost N
Paracetamol absorption test to detect poor enteric absorption of oseltamivir in intensive care unit patients with severe influenza: a pilot study.
Intensive Care Medicine 2019, 45, 1484-1486.

Le Hingrat Q, Charpentier C, Ghosn J, Thiébaut R, Peytavin G, Descamps D, Matheron S
New insights are game-changers in HIV-2 disease management.
The lancet. HIV 2019, 6, e214.

Eholie SP, Moh R, Benalycherif A, Gabillard D, Ello F, Messou E, Zoungrana J, Diallo I, Diallo M, Bado G, Cisse M, Maiga AI, Anzian A, Toni Td, Congo-Ouedraogo M, Toure-Kane C, Seydi M, Minta DK, Sawadogo A, Sangaré L, Drabo J, Karcher S, Le Carrou J, de Monteynard LA, Peytavin G, Gabassi A, Girard PM, Chaix ML, Anglaret X, Landman R, TA1SG
Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study.
The lancet. HIV 2019, 6, e750-e759.

Le Hingrat Q, Collin G, Lê M, Peytavin G, Visseaux B, Bertine M, Tubiana R, Karmochkine M, Valin N, Collin F, Lemaignen A, Bernard L, Damond F, Matheron S, Descamps D, Charpentier C, FNAfRoAaVH(CH2C
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019, 69, 657-667.

Ngo-Giang-Huong N, Huynh THK, Dagnra AY, Toni Td, Maiga AI, Kania D, Eymard-Duvernay S, Peeters M, Soulie C, Peytavin G, Rekacewicz C, Chaix ML, Aghokeng AF, A1SG, Aghokeng AF, Ayouba A, Brun-Vézinet F, Chaix ML, Calvez V, Dagnra A, Descamps D, Dramane K, Fournier I, Maiga A, de Monteynard LA, Nouhin J, Kane CT, Lien TX, Ngo-Giang-Huong N, Peeters M, Plantier JC, Njouom R, Tuaillon E, Rekacewicz C, d’Aquin TT, Poda A, Zougrana J, Ouedraogo S, Ouedraogo M, Djeuda AD, Kouanfack C, Mandeng N, Mpoudi-Ngole E, Messou E, Jacques DJ, Nguessan JF, Dolo O, Diarra Z, Cisse M, Patassi A, Salou M, Ali-Edjé K, Bowonwatanuwong C, Thongpaen S, Klinbuayaem V, Laomanit L, Luong QA, Tran T
Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries.
Journal of Antimicrobial Chemotherapy 2019, 74, 462-467.

Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y, LSG
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
The Journal of Antimicrobial Chemotherapy 2019, 74, 739-745.

Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D, AA4RSG
Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1417-1424.

Néant N, Solas C, Bouazza N, Lê MP, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Gattacceca F
Concentration–response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients.
Journal of Antimicrobial Chemotherapy 2019, 74, 1992-2002.

Castain L, Perrier M, Charpentier C, Palich R, Desire N, Wirden M, Descamps D, Sayon S, Landman R, Valantin MA, Joly V, Peytavin G, Yazdanpanah Y, Katlama C, Calvez V, Marcelin AG, Todesco E
New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
The Journal of Antimicrobial Chemotherapy 2019, 74, 2019-2023.

Katlama C, Assoumou L, Valantin MA, Soulié C, Martinez E, Béniguel L, Bouchaud O, Raffi F, Molina JM, Fellahi S, Peytavin G, Marcelin AG, Kolta S, Capeau J, Gibowski S, Cardon F, Reynes J, Costagliola D, tmotA1Es, Bernard L, Bottero J, Bouchaud O, Chidiac C, Duvivier C, Goujard C, delMarGutiérrez M, Martinez E, Molina JM, Morlat P, Naqvi A, Podzamczer D, Poizot-Martin I, Raffi F, Reynes J, Salmon-Céron D, Simon A, Valantin MA, Weiss L, Yazdanpanah Y
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
Journal of Antimicrobial Chemotherapy 2019, 74, 2742-2751.

Valantin MA, Durand L, Wirden M, Assoumou L, Caby F, Soulié C, Nguyen TTT, Tubiana R, Kirstetter M, Junot H, Marcelin AG, Peytavin G, Tilleul P, Katlama C
Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study.
Journal of Antimicrobial Chemotherapy 2019, 74, 2716-2722.

Pommier JD, Laouénan C, Michard F, Papot E, Urios P, Boutten A, Peytavin G, Ghander C, Lariven S, Castanedo G, Moho D, Landman R, Phung B, Perez E, Julia Z, Descamps D, Roland-Nicaise P, Le Gac S, Yazdanpanah Y, Guibourdenche J, Yeni P
Metabolic syndrome and endocrine status in HIV-infected transwomen.
AIDS (London, England) 2019, 33, 855-865.

Lê MP, Chaix M, Raffi F, Chevret S, Gallien S, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina J, Peytavin G, tADsg
Once‐daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS ‐165 DARULIGHT study.
British Journal of Clinical Pharmacology 2019, 85, 277-280.

Stefic K, Guinard J, Peytavin G, Saboni L, Sommen C, Sauvage C, Lot F, Laperche S, Velter A, Barin F, Pwg
Screening for Human Immunodeficiency Virus infection using a fourth-generation antigen/antibody assay and dried blood spots: in depth analysis of sensitivity and performance assessment in a cross-sectional study.
Journal of Clinical Microbiology 2019

Gantner P, Sylla B, Morand-Joubert L, Frange P, Lacombe K, Khuong MA, Duvivier C, Launay O, Karmochkine M, Arvieux C, Ménard A, Piroth L, Canestri A, Trias D, Peytavin G, Landman R, Ghosn J, obotCISG, Güerri-Fernández R
“Real life” use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study.
PLOS ONE 2019, 14, e0216010.

Mandelbrot L, Ceccaldi PF, Duro D, Lê M, Pencolé L, Peytavin G, Spradley FT
Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model.
PLOS ONE 2019, 14, e0220323.

Basilua JM, Sawoo O, Mangin I, Dossou-Yovo F, Boussard A, Chevillard L, Lutete GT, Eto B, Peytavin G, Pochart P
Higher Atazanavir Plasma Exposure in Rats is Associated with Gut Microbiota Changes Induced by Cotrimoxazole.
Current Drug Metabolism 2019, 20, 898-906.

Perrineau S, Lachâtre M, Lê MP, Rioux C, Loubet P, Fréchet-Jachym M, Gonzales MC, Grall N, Bouvet E, Veziris N, Yazdanpanah Y, Peytavin G
Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
The International Journal of Tuberculosis and Lung Disease 2019, 23, 99-104.

2018


Néant N, Gattacceca F, Lê MP, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Solas C
Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.
European Journal of Clinical Pharmacology 2018, 74, 473-481.

Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L, Mortier E, Charpentier C, Tubiana R, Damond F, Peytavin G, Ponscarme D, Collin F, Brun-Vezinet F, Chene G, A1H2tSG
First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2).
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2018

Seang S, Schneider L, Nguyen T, Lê MP, Soulie C, Calin R, Caby F, Valantin MA, Tubiana R, Assoumou L, Marcelin AG, Peytavin G, Katlama C
Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia.
The Journal of Antimicrobial Chemotherapy 2018, 73, 490-493.

Le Meur L, Tantet C, Lê MP, Desselas E, Bonnal C, Lillo-Le-Louet A, Sonneville R, Massias L, Giraud J, Descamps D, Yazdanpanah Y, Lariven S, Peytavin G
Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis.
The Journal of Antimicrobial Chemotherapy 2018, 73, 1108-1110.

Charpentier C, Peytavin G, Lê MP, Joly V, Cabras O, Perrier M, Le Gac S, Phung B, Yazdanpanah Y, Descamps D, Landman R
High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.
The Journal of Antimicrobial Chemotherapy 2018, 73, 1665-1671.

Molina JM, Gallien S, Chaix ML, El Abbassi EM, Madelaine I, Katlama C, Valin N, Delobel P, Desseaux K, Peytavin G, Saillard J, Raffi F, Chevret S, A1DSG
Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight).
The Journal of Antimicrobial Chemotherapy 2018

Lê MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G, A1DSG
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
The Journal of Antimicrobial Chemotherapy 2018, 73, 2120-2128.

Nguyen T, Fofana DB, Lê MP, Charpentier C, Peytavin G, Wirden M, Lambert-Niclot S, Desire N, Grude M, Morand-Joubert L, Flandre P, Katlama C, Descamps D, Calvez V, Todesco E, Marcelin AG
Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing.
The Journal of Antimicrobial Chemotherapy 2018, 73, 2485-2492.

Fofana DB, d'Almeida M, Lambert-Niclot S, Peytavin G, Girard PM, Lafia B, Zohoun-Guidigbi L, Keke RK, Soulie C, Marcelin AG, Morand-Joubert L
Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West Africa.
The Journal of Antimicrobial Chemotherapy 2018

Todesco E, Mazzola A, Akhavan S, Abravanel F, Poynard T, Roque-Afonso AM, Peytavin G, Marcelin AG, Calmus Y, Lecuyer L, Guillemain R, Conti F
Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective.
Antiviral Therapy 2018

Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G, Aumaitre H, Alric L, Boué F, Morlat P, Poizot-Martin I, Billaud E, Rosenthal E, Naqvi A, Miailhes P, Bani-Sadr F, Esterle L, Carrieri P, Dabis F, Sogni P, Wittkop L, ACHsG
Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients.
World Journal of Hepatology 2018, 10, 856-866.

2017


Pourcher G, Peytavin G, Schneider L, Gallien S, Force G, Pourcher V
Bariatric surgery in HIV patients: experience of an Obesity Reference Center in France.
Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery 2017, 13, 1990-1996.

Pourcher V, Desnoyer A, Assoumou L, Lebbe C, Curjol A, Marcelin AG, Cardon F, Gibowski S, Salmon D, Chennebault JM, Poizot-Martin I, Peytavin G, Boué F, Costagliola D
Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial.
AIDS research and human retroviruses 2017, 33, 1–10.

Calvez V, Hocqueloux L, Meynard JL, Muret P, Castan B, Tardy JC, Peytavin G, Landman R
Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why?.
The Journal of Antimicrobial Chemotherapy 2017, 72, 19-28.

Fonsart J, Saragosti S, Taouk M, Peytavin G, Bushman L, Charreau I, Hance A, Goldwirt L, Morel S, Mammano F, Loze B, Capitant C, Clavel F, Mahjoub N, Meyer L, Anderson PL, Delaugerre C, Molina JM
Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.
The Journal of Antimicrobial Chemotherapy 2017, 72, 478–485.

Wirden M, Charpentier C, Tubiana R, Le MP, Desire N, Dionou S, Pichon F, Valantin MA, Yasdanpanah Y, Descamps D, Peytavin G, Katlama C, Calvez V, Marcelin AG
HIV-1 diagnosis with unquantifiable viraemia: don't be naive, look for antiretroviral drugs.
The Journal of Antimicrobial Chemotherapy 2017, 72, 630-632.

Madelain V, Le MP, Champenois K, Charpentier C, Landman R, Joly V, Yeni P, Descamps D, Yazdanpanah Y, Peytavin G
Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1137-1146.

Perrier M, Charpentier C, Peytavin G, Lê M, Blondel L, Visseaux B, Joly V, Pinto A, Matheron S, Yazdanpanah Y, Descamps D, Landman R
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1745-1751.

Lê MP, Belarbi L, Chaix ML, Dulioust E, Mahjoub N, Salmon D, Viard JP, Duvivier C, Peytavin G, Launay O, Ghosn J
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
The Journal of Antimicrobial Chemotherapy 2017, 72, 3167-3171.

Crowell CS, Maiga AI, Sylla M, Taiwo B, Kone N, Oron AP, Murphy RL, Marcelin AG, Traore B, Fofana DB, Peytavin G, Chadwick EG
High Rates of Baseline Drug Resistance and Virologic Failure Among ART-naive HIV-infected Children in Mali.
The Pediatric Infectious Disease Journal 2017, 36, e258-e263.

Papot E, Landman R, Louni F, Charpentier C, Peytavin G, Certain A, Fradet C, Castro DR, Preau M, Goujard C, Yeni P, Yazdanpanah Y, AGSG
Budget impact of antiretroviral therapy in a French clinic cohort.
AIDS (London, England) 2017, 31, 1271-1279.

Todesco E, Demeret S, Calin R, Roque-Afonso AM, Thibault V, Mallet V, Akhavan S, Jaspard M, Peytavin G, Poynard T, Katlama C, Pourcher V
Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin.
AIDS (London, England) 2017, 31, 1346-1348.

Bardon VF, Mandelbrot L, Duro D, Dussaux C, Le M, Peytavin G
Placental transfer of elvitegravir and cobicistat in an Ex Vivo human cotyledon double perfusion model.
AIDS (London, England) 2017

Desvignes C, Becquart C, Launay D, Terriou L, Patenotre P, Deheul S, Peytavin G, Dupin N, Delaporte E, Staumont-Sallé D
Extensive levamisole-induced vasculitis.
Clinical and Experimental Dermatology 2017

Gantner P, Cuzin L, Allavena C, Cabie A, Pugliese P, Valantin MA, Bani-Sadr F, Joly V, Ferry T, Poizot-Martin I, Garraffo R, Peytavin G, Fafi-Kremer S, Rey D, Dsg
Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.
HIV medicine 2017, 18, 704-708.

2016


Delory T, Papot E, Rioux C, Charpentier C, Auge-Courtoi C, Michard F, Peytavin G, Descamps D, Matheron S, Yazdanpanah Y
Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.
Journal of Medical Virology 2016, 88, 1204-1210.

Desnoyer A, Pospai D, Lê MP, Gervais A, Heurgué-Berlot A, Laradi A, Harent S, Pinto A, Salmon D, Hillaire S, Fontaine H, Zucman D, Simonpoli AM, Muret P, Larrouy L, Bernard Chabert B, Descamps D, Yazdanpanah Y, Peytavin G
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
Journal of Hepatology 2016, 65, 40-47.

Frange P, Faye A, Avettand-Fenoël V, Bellaton E, Descamps D, Angin M, David A, Caillat-Zucman S, Peytavin G, Dollfus C, Le Chenadec J, Warszawski J, Rouzioux C, Sáez-Cirión A, AECPCatAEVsg
HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.
The lancet. HIV 2016, 3, e49–54.

Slama L, Landman R, Assoumou L, Benalycherif A, Samri A, Joly V, Pialoux G, Valin N, Cabié A, Duvivier C, Lambert-Niclot S, Marcelin AG, Peytavin G, Costagliola D, Girard PM, I0DSG
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
The Journal of Antimicrobial Chemotherapy 2016, 71, 2252–2261.

Bocket L, Peytavin G, Alidjinou EK, Ajana F, Choisy P, Lê M, Charpentier C, Descamps D, Yazdanpanah Y, Katlama C, Simon A, Calvez V, Marcelin AG, Soulie C
Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
The Journal of Antimicrobial Chemotherapy 2016, 71, 2651-2653.

Katlama C, Soulié C, Caby F, Denis A, Blanc C, Schneider L, Valantin MA, Tubiana R, Kirstetter M, Valdenassi E, Nguyen T, Peytavin G, Calvez V, Marcelin AG
Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia.
The Journal of Antimicrobial Chemotherapy 2016, 71, 2646–2650.

de Truchis P, Lê MP, Daou M, Madougou B, Nouhou Y, Moussa Saley S, Sani A, Adehossi E, Rouveix E, Saidou M, Peytavin G, Delaugerre C
High efficacy of first-line ART in a West African cohort, assessed by dried blood spot virological and pharmacological measurements.
The Journal of Antimicrobial Chemotherapy 2016, 71, 3222-3227.

Jean K, Puren A, Cutler E, Singh B, Bouscaillou J, Rain-Taljaard R, Taljaard D, Gouws E, Lissouba P, Lewis DA, Peytavin G, Auvert B
Level of viral suppression and the cascade of HIV care in a South African semi-urban setting in 2012.
AIDS (London, England) 2016, 30, 2107-2116.

De Sousa Mendes M, Hirt D, Vinot C, Valade E, Lui G, Pressiat C, Bouazza N, Foissac F, Blanche S, Lê MP, Peytavin G, Treluyer JM, Urien S, Benaboud S
Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.
British Journal of Clinical Pharmacology 2016, 81, 646–657.

Desnoyer A, Dupin N, Assoumou L, Carlotti A, Gaudin F, Deback C, Peytavin G, Marcelin AG, Boué F, Balabanian K, Pourcher-Martinez V, A1Ltg
Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi's sarcoma skin lesions.
The British Journal of Dermatology 2016

Vinot C, Tréluyer JM, Giraud C, Gavard L, Peytavin G, Mandelbrot L
Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.
Antimicrobial Agents and Chemotherapy 2016, 60, 3112-3114.

2015


Laouenan C, Guedj J, Peytavin G, Nguyen TT, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hezode C, Carrat F, Nicot F, Marcellin P, Mentre F
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy.
CPT Pharmacometrics Syst Pharmacol 2015, 4, e00008.

Wagner N, Wyler-Lazarevic CA, Yerly S, Samer C, Peytavin G, Posfay-Barbe KM, Calmy A, Ambrosioni J
Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review.
New Microbes and New Infections 2015, 6, 1–4.

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF, AISG
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
The New England Journal of Medicine 2015, 373, 2237–2246.

Soulie C, Peytavin G, Charpentier C, Lambert-Niclot S, Sayon S, Visseaux B, Simon A, Katlama C, Yazdanpanah Y, Descamps D, Calvez V, Marcelin AG
Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.
AIDS research and human retroviruses 2015, 31, 475-478.

Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, Charpentier C, Khuong-Josses MA, Duvivier C, Karmochkine M, Lukiana T, Matheron S
Dolutegravir in HIV-2 infected patients with resistant virus to first-line integrase inhibitors from the French Named Patient Program.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2015

Lê MP, Landman R, Koulla-Shiro S, Charpentier C, Sow PS, Diallo MB, Ngom Gueye NF, Ngolle M, Le Moing V, Eymard-Duvernay S, Benalycherif A, Delaporte E, Girard PM, Peytavin G, DSG
Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1517–1521.

Danion F, Belissa E, Peytavin G, Thierry E, Lanternier F, Scemla A, Lortholary O, Delelis O, Avettand-Fenoel V, Duvivier C
Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1921–1923.

Raymond S, Maillard A, Amiel C, Peytavin G, Trabaud MA, Desbois D, Bellecave P, Delaugerre C, Soulie C, Marcelin AG, Descamps D, Izopet J, obtAARSG
Virological failure of patients on maraviroc-based antiretroviral therapy.
The Journal of Antimicrobial Chemotherapy 2015

Wirden M, Todesco E, Valantin MA, Lambert-Niclot S, Simon A, Calin R, Tubiana R, Peytavin G, Katlama C, Calvez V, Marcelin AG
Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice.
The Journal of Antimicrobial Chemotherapy 2015

Lê MP, Soulié C, Assoumou L, Valantin MA, Duvivier C, Chas J, Ponscarme D, Marcelin AG, Calvez V, Katlama C, Peytavin G, RA1SG
Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.
The Journal of Antimicrobial Chemotherapy 2015, 70, 2418–2420.

Soulié C, Assoumou L, Darty M, Rodriguez C, Donati F, Sayon S, Peytavin G, Valantin MA, Caby F, Schneider L, Canestri A, Costagliola D, Katlama C, Calvez V, Marcelin AG, RA1SG
Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).
The Journal of Antimicrobial Chemotherapy 2015, 70, 3339–3344.

Cazanave C, Reigadas S, Mazubert C, Bellecave P, Hessamfar M, Le Marec F, Lazaro E, Peytavin G, Bruyand M, Fleury H, Dabis F, Neau D
Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014.
Open Forum Infectious Diseases 2015, 2, ofv018.

Alessandri-Gradt E, Morgand M, Delaugerre C, Peytavin G, Sellier P, Simon F, Plantier JC
HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
AIDS (London, England) 2015, 29, 1271–1273.

Zucman D, Sené T, Hillaire S, Kahn JE, Farfour E, Peytavin G
Antihepatitis C virus treatments for HIV-hepatitis C virus coinfected cirrhotic patients: a need to look beyond the sustained viral response.
AIDS (London, England) 2015, 29, 1903–1904.

Boullé C, Kouanfack C, Laborde-Balen G, Boyer S, Aghokeng AF, Carrieri MP, Kazé S, Dontsop M, Mben JM, Koulla-Shiro S, Peytavin G, Spire B, Delaporte E, Laurent C, SA1SG
Gender Differences in Adherence and Response to Antiretroviral Treatment in the Stratall Trial in Rural District Hospitals in Cameroon.
Journal of Acquired Immune Deficiency Syndromes (1999) 2015, 69, 355–364.

Polivka L, Peytavin G, Franck N, Mouthon L, Dupin N
Testing for levamisole and cocaine in hair samples for the diagnosis of levamisole-related panniculitis.
Journal of the European Academy of Dermatology and Venereology: JEADV 2015, 29, 2487–2489.

Mandelbrot L, Duro D, Belissa E, Peytavin G
Placental transfer of rilpivirine in an ex vivo human cotyledon perfusion model.
Antimicrobial Agents and Chemotherapy 2015, 59, 2901-2903.

Pain JB, Lê MP, Caseris M, Amiel C, Lassel L, Charpentier C, Desnoyer A, Farnoux C, Pialoux G, Descamps D, Peytavin G
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
Antimicrobial Agents and Chemotherapy 2015, 59, 3660–3662.

Mandelbrot L, Duro D, Belissa E, Peytavin G
Erratum for Mandelbrot et al., placental transfer of rilpivirine in an ex vivo human cotyledon perfusion model.
Antimicrobial Agents and Chemotherapy 2015, 59, 5869.

Charpentier C, Lê MP, Joly V, Visseaux B, Lariven S, Phung B, Yéni P, Yazdanpanah Y, Descamps D, Peytavin G, Landman R
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.
PloS One 2015, 10, e0134430.

Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D, ACH2C
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
PloS One 2015, 10, e0134904.

Lê MP, Mandelbrot L, Descamps D, Soulié C, Ichou H, Bourgeois-Moine A, Damond F, Lariven S, Valantin MA, Landman R, Faucher P, Tubiana R, Duro D, Meier F, Legac S, Bourse P, Mortier E, Dommergues M, Calvez V, Matheron S, Peytavin G
Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
Antiviral Therapy 2015, 20, 507-513.

2014


Boyd A, Gozlan J, Maylin S, Delaugerre C, Peytavin G, Girard PM, Zoulim F, Lacombe K
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
Hepatology (Baltimore, Md.) 2014, 60, 497–507.

Camara S, Zucman D, Vasse M, Goudjo A, Guillard E, Peytavin G
[Lack of bioavailability of generic lopinavir/ritonavir not prequalified by WHO marketed in Africa (Congo Brazzaville).].
Bulletin De La Societe De Pathologie Exotique (1990) 2014

Caby F, Schneider L, Blanc C, Soulié C, Tindel M, Peytavin G, Agher R, Valantin MA, Tubiana R, Wirden M, Calvez V, Marcelin AG, Katlama C
Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score.
Infection 2014, 42, 295–301.

Leporrier J, Etienne M, Chapuzet C, Peytavin G, Bord S, Borsa-Lebas F, Caron F, Plantier JC, Mourez T
Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2014, 60, 428–430.

Loubet P, Charpentier C, Visseaux B, Nuta C, Adu E, Chapplain JM, Baysah M, Walters-Doe S, Tattevin P, Peytavin G, Yazdanpanah Y, Descamps D
Short communication: Prevalence of HIV-1 transmitted drug resistance in Liberia.
AIDS research and human retroviruses 2014, 30, 863-866.

Katlama C, Assoumou L, Valantin MA, Soulié C, Duvivier C, Chablais L, Kolta S, Pialoux G, Mercié P, Simon A, Costagliola D, Peytavin G, Marcelin AG, RA1SG
Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
The Journal of Antimicrobial Chemotherapy 2014, 69, 1648–1652.

Charpentier C, Choquet M, Joly V, Yeni P, Visseaux B, Caseris M, Brun-Vézinet F, Yazdanpanah Y, Peytavin G, Descamps D, Landman R
Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.
The Journal of Antimicrobial Chemotherapy 2014, 69, 2819-2825.

Zucman D, Camara S, Gravisse J, Dimi S, Vasse M, Goudjo A, Choquet M, Peytavin G
Generic antiretroviral drugs in developing countries: friends or foes?.
AIDS (London, England) 2014, 28, 607–609.

Charpentier C, Eholié S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoël V, Messou E, Minga A, Damond F, Plantier JC, Dabis F, Peytavin G, Brun-Vézinet F, Ekouevi DK, IWAC
Genotypic resistance profiles of HIV-2-treated patients in West Africa.
AIDS (London, England) 2014, 28, 1161–1169.

Nguyen LBL, Harent S, Peytavin G, Visseaux B, Bastard JP, Dubourg O, Lariven S, Patrick Yeni n, Yazdanpanah Y, Lescure FX
Skeletal muscle toxicity associated with emtricitabine/rilpivirine/tenofovir fixed-dose combination: a case report.
AIDS (London, England) 2014, 28, 1995-1997.

Laouénan C, Marcellin P, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hézode C, Carrat F, Nicot F, Peytavin G, Mentré F, Guedj J
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.
Antimicrobial Agents and Chemotherapy 2014, 58, 5332-5341.

Mandelbrot L, Duro D, Belissa E, Peytavin G
Placental transfer of darunavir in an ex vivo human cotyledon perfusion model.
Antimicrobial Agents and Chemotherapy 2014, 58, 5617-5620.

Landman R, Koulla-Shiro S, Sow PS, Ngolle M, Diallo MB, Guèye NFN, Le Moing V, Eymard-Duvernay S, Benalycherif A, Charpentier C, Peytavin G, Delaporte E, Girard PM, DSG
Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
Antiviral Therapy 2014, 19, 51–59.

Reliquet V, Chirouze C, Allavena C, Muret P, Peytavin G, André-Garnier E, Bettinger D, Ferré V, Hoen B, Raffi F
Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Antiviral Therapy 2014, 19, 117–123.

2013


Steff M, Joly V, Di Lucca J, Feldman J, Burg S, Sarda-Mantel L, Peytavin G, Marinho E, Crickx B, Raymond E, Lariven S, Maubec E
Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma.
JAMA dermatology 2013, 149, 1319-1322.

Ghosn J, Slama L, Chermak A, Houssaini A, Lambert-Niclot S, Schneider L, Fourn E, Duvivier C, Simon A, Courbon E, Murphy R, Flandre P, Peytavin G, Katlama C, RSG
Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.
Journal of Medical Virology 2013, 85, 8-15.

Lê MP, Stitou H, Soulie C, Katlama C, Peytavin G
Sialolithiasis in an HIV-1-infected patient treated with atazanavir/ritonavir monotherapy.
The Journal of Antimicrobial Chemotherapy 2013, 68, 727-729.

Lê MP, Gervais A, Le Beller C, Long K, Larrouy L, Papy E, Mal H, Descamps D, Peytavin G
Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir.
The Journal of Antimicrobial Chemotherapy 2013, 68, 1208-1209.

Todesco E, Sayon S, Fourati S, Tubiana R, Simon A, Ktorza N, Schneider L, Peytavin G, Malet I, Van den Eede P, Katlama C, Calvez V, Marcelin AG, Wirden M
Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies.
The Journal of Antimicrobial Chemotherapy 2013, 68, 2882-2889.

Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Peytavin G, Roque-Afonso AM, Vittecoq D, Samuel D, Taburet AM, Duclos-Vallée JC
Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft.
AIDS (London, England) 2013, 27, 2655-2657.

Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vézinet F, Plantier JC, Descamps D
In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
AIDS (London, England) 2013, 27, 2959-2961.

Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D, ACH2C
Transmitted drug resistance in French HIV-2-infected patients.
AIDS 2013, 27, 1671–1674.

Descours B, Lambert-Niclot S, Mory B, Samri A, Charlotte F, Peytavin G, Tubiana R, Papagno L, Bacchus C, Lecardonnel F, Katlama C, Autran B, Marcelin AG, Valantin MA, Carcelain G, DaOSG
Direct quantification of cell-associated HIV DNA in isolated rectal and blood memory CD4 T cells revealed their similar and low infection levels in long-term treated HIV-infected patients.
Journal of Acquired Immune Deficiency Syndromes (1999) 2013, 62, 255-259.

Semaille C, Barin F, Bouyssou A, Peytavin G, Guinard J, Le Vu S, Pillonel J, Spire B, Velter A
High viral loads among HIV-positive MSM attending gay venues: implications for HIV transmission.
Journal of Acquired Immune Deficiency Syndromes (1999) 2013, 63, e122-124.

Clavel-Osorio C, Cazassus F, Stegmann S, Huc-Anaïs P, Lecam D, Peytavin G
One-month transplacental pharmacokinetics of raltegravir in a premature newborn after short-course treatment of the HIV-1-infected mother.
Antimicrobial Agents and Chemotherapy 2013, 57, 6393-6394.

Vinot C, Gavard L, Tréluyer JM, Manceau S, Courbon E, Scherrmann JM, Declèves X, Duro D, Peytavin G, Mandelbrot L, Giraud C
Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.
Antimicrobial Agents and Chemotherapy 2013, 57, 1415-1420.

Abgrall S, Le Bel J, Lele N, Laouénan C, Eychenne N, Mentré F, Peytavin G, Bouchaud O, VSG
Lack of effect of doxycycline on trough concentrations of protease inhibitors or non-nucleoside reverse transcriptase inhibitors in HIV-infected patients.
HIV clinical trials 2013, 14, 313-318.

Auvert B, Taljaard D, Rech D, Lissouba P, Singh B, Bouscaillou J, Peytavin G, Mahiane SG, Sitta R, Puren A, Lewis D
Association of the ANRS-12126 male circumcision project with HIV levels among men in a South African township: evaluation of effectiveness using cross-sectional surveys.
PLoS medicine 2013, 10, e1001509.

Zucman D, De Truchis P, Peytavin G, Descamps D, Duvivier C, Tegna L, Weiss L, Delassus JL, Benalycherif A, Landman R
Efficacy, safety, and pharmacokinetics of once-daily boosted darunavir in pretreated HIV-infected patients.
Scandinavian Journal of Infectious Diseases 2013, 45, 407-410.

2012


Fourati S, Malet I, Guenzel CA, Soulie C, Maidou-Peindara P, Morand-Joubert L, Wirden M, Sayon S, Peytavin G, Simon A, Katlama C, Benichou S, Calvez V, Marcelin AG
E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations.
Antiviral Research 2012, 93, 167-174.

Courbon E, Laylavoix F, Soulié C, Le Beller C, Calvez V, Katlama C, Peytavin G
Unexpected atazanavir-associated biliary lithiasis in an HIV-infected patient.
The Journal of Antimicrobial Chemotherapy 2012, 67, 250-251.

Dominguez S, Ghosn J, Cassard B, Melica G, Poizot-Martin I, Solas C, Lascaux AS, Bouvier-Alias M, Katlama C, Lévy Y, Peytavin G
Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.
The Journal of Antimicrobial Chemotherapy 2012, 67, 1449-1452.

Lambert-Niclot S, Flandre P, Valantin MA, Peytavin G, Sayon S, Morand-Joubert L, Delaugerre C, Algarte-Genin M, Katlama C, Calvez V, Marcelin AG
Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
The Journal of Antimicrobial Chemotherapy 2012, 67, 1470-1474.

Lambert-Niclot S, Masquelier B, Cohen Codar I, Soulie C, Delaugerre C, Morand-Joubert L, Charpentier C, Ferre V, Plantier JC, Montes B, Carret S, Perrot V, Peytavin G, Costagliola D, Calvez V, Marcelin AG, ESG
Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
The Journal of Antimicrobial Chemotherapy 2012, 67, 2487-2493.

Lê MP, Solas C, Garraffo R, Gagnieu MC, Muret P, Yeni P, Dhiver C, Katlama C, Poizot-Martin I, Durant J, Peytavin G
Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
The Journal of Antimicrobial Chemotherapy 2012, 67, 2779-2781.

Solas C, Pambrun E, Winnock M, Salmon D, Poizot-Martin I, Dominguez S, Bani-Sadr F, Izopet J, Garraffo R, Peytavin G, AC1HSG
Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?.
AIDS (London, England) 2012, 26, 2193-2199.

Cuzin L, Trabelsi S, Delobel P, Barbuat C, Reynes J, Allavena C, Peytavin G, Ghosn J, Lascoux-Combe C, Psomas C, Corbeau P, Flandre P, A1MSg
Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.
Journal of Acquired Immune Deficiency Syndromes (1999) 2012, 61, 557-564.

Lada O, Gervais A, Branger M, Peytavin G, Roquebert B, Collin G, Fraqueiro G, Moucari R, Hamet G, Martinot-Peignoux M, Matheron S, Marcellin P
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Liver International: Official Journal of the International Association for the Study of the Liver 2012, 32, 93-101.

Visseaux B, Charpentier C, Hurtado-Nedelec M, Storto A, Antoine R, Peytavin G, Damond F, Matheron S, Brun-Vézinet F, Descamps D, FAH2C(C0V2
In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Antimicrobial Agents and Chemotherapy 2012, 56, 137-139.

Clavel C, Peytavin G, Tubiana R, Soulié C, Courbon E, Crenn-Hebert C, Ichou H, Blanc C, Schneider L, Katlama C, Marcelin AG, Mandelbrot L
Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study.
Antimicrobial Agents and Chemotherapy 2012, 56, 4018-4020.

Lazareth H, Peytavin G, Polivka L, Dupin N
The hairy-print for levamisole-induced vasculitis.
BMJ case reports 2012, 2012,

Schneider L, Ktorza N, Fourati S, Assoumou L, Courbon E, Caby F, Blanc C, Tindel M, Agher R, Marcelin AG, Calvez V, Peytavin G, Katlama C
Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
HIV clinical trials 2012, 13, 284-288.

Le Vu S, Velter A, Meyer L, Peytavin G, Guinard J, Pillonel J, Barin F, Semaille C
Biomarker-based HIV incidence in a community sample of men who have sex with men in Paris, France.
PloS One 2012

Lada O, Gervais A, Branger M, Peytavin G, Roquebert B, Collin G, Fraqueiro G, Moucari R, Leclerc L, Martinot-Peignoux M, Matheron S, Marcellin P
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Antiviral Therapy 2012, 17, 61-70.

Calin R, Paris L, Simon A, Peytavin G, Wirden M, Schneider L, Valantin MA, Tubiana R, Agher R, Katlama C
Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.
Antiviral Therapy 2012, 17, 1601-1604.

2011


Mandelbrot L, Mazy F, Floch-Tudal C, Meier F, Azria E, Crenn-Hebert C, Treluyer JM, Herinomenzanahary E, Ferreira C, Peytavin G
Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.
European Journal of Obstetrics, Gynecology, and Reproductive Biology 2011, 157, 18-21.

Clavel C, Peytavin G, Tubiana R, Soulié C, Crenn-Hebert C, Heard I, Bissuel F, Ichou H, Ferreira C, Katlama C, Marcelin AG, Mandelbrot L
Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).
Antimicrobial Agents and Chemotherapy 2011, 55, 3018-3021.

2009


Gavard L, Beghin D, Forestier F, Cayre Y, Peytavin G, Mandelbrot L, Farinotti R, Gil S
Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir.
European Journal of Obstetrics, Gynecology, and Reproductive Biology 2009, 147, 157-160.

Bénard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F, Autran B, Brun-Vézinet F, Chêne G, Matheron S, ACH2CSG
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
AIDS (London, England) 2009, 23, 1171-1173.

Duval X, Mentré F, Rey E, Auleley S, Peytavin G, Biour M, Métro A, Goujard C, Taburet AM, Lascoux C, Panhard X, Tréluyer JM, Salmon-Céron D, C2SG
Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial.
Fundamental & Clinical Pharmacology 2009, 23, 491-500.

2008


Ceccaldi PF, Ferreira C, Gavard L, Gil S, Peytavin G, Mandelbrot L
Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model.
American Journal of Obstetrics and Gynecology 2008, 198, 433.e1-2.

Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D, FAH2C(C0V2
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
The Journal of Antimicrobial Chemotherapy 2008, 62, 914-920.

Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, Toledano D, Descamps D, Brun-Vezinet F, Matheron S
Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients.
AIDS (London, England) 2008, 22, 665-666.

Roquebert B, Blum L, Collin G, Damond F, Peytavin G, Leleu J, Matheron S, Chêne G, Brun-Vézinet F, Descamps D, AH2CC
Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
AIDS (London, England) 2008, 22, 2045-2046.

Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Bénard A, Campa P, Matheron S, Chêne G, Brun-Vézinet F, Descamps D, FAH2C(C0V2
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Antimicrobial Agents and Chemotherapy 2008, 52, 1545-1548.

2007


Collin F, Chêne G, Retout S, Peytavin G, Salmon D, Bouvet E, Raffi F, Garraffo R, Mentré F, Duval X, ACACSG
Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults.
Therapeutic Drug Monitoring 2007, 29, 164-170.

Duval X, Peytavin G, Breton G, Ecobichon JL, Descamps D, Thabut G, Leport C
Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination.
AIDS (London, England) 2007, 21, 106-108.

Essig M, Duval X, Kaied FA, Iordache L, Gervais A, Longuet P, Blanchet F, Peytavin G, Leport C
Is phosphatemia the best tool to monitor renal tenofovir toxicity?.
Journal of Acquired Immune Deficiency Syndromes (1999) 2007, 46, 256-258.

2006


Gavard L, Gil S, Peytavin G, Ceccaldi PF, Ferreira C, Farinotti R, Mandelbrot L
Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model.
American Journal of Obstetrics and Gynecology 2006, 195, 296-301.

Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, Pueyo S, Brun-Vezinet F, Chene G, ACHCSG
CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort.
AIDS (London, England) 2006, 20, 459-462.

Launay O, Duval X, Dalban C, Descamps D, Peytavin G, Certain A, Mouajjah S, Ralaimazava P, Verdon R, Costagliola D, Clavel F, A1VSG
Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Antiviral Therapy 2006, 11, 889-899.

2005


Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S, Mammano F, Lastere S, Farfara I, Simon F, Chene G, Descamps D
Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.
Journal of Clinical Microbiology 2005, 43, 484-487.

Duval X, Mentré F, Lamotte C, Chêne G, Spire B, Dellamonica P, Panhard X, Salmon D, Raffi F, Peytavin G, Leport C, ASG
Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.
Therapeutic Drug Monitoring 2005, 27, 63-70.

Duval X, Descamps D, Breton G, Darmon S, Ecobichon JL, Delarue S, Peytavin G, Leport C, Vildé JL, Brun-Vézinet F
Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia.
Antiviral Therapy 2005, 10, 197-199.

Verstuyft C, Marcellin F, Morand-Joubert L, Launay O, Brendel K, Mentré F, Peytavin G, Gérard L, Becquemont L, Aboulker JP, ASG
Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy.
AIDS (London, England) 2005, 19, 2127-2131.

Damond F, Collin G, Matheron S, Peytavin G, Campa P, Delarue S, Taieb A, Bénard A, Chêne G, Brun-Vézinet F, Descamps D, FAH2C(C5V2
Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene.
Antiviral Therapy 2005, 10, 861-865.

Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet AM, CA1SG
High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Clinical Pharmacokinetics 2005, 44, 1267-1278.

2004


Breton G, Alexandre M, Duval X, Prie D, Peytavin G, Leport C, Vildei JL
Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
Scandinavian Journal of Infectious Diseases 2004, 36, 527-528.

Duval X, Peytavin G, Albert I, Bénoliel S, Ecobichon JL, Brun-Vézinet F, Mentré F, Leport C, Vildé JL
Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
HIV medicine 2004, 5, 307-313.

Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.
Antimicrobial Agents and Chemotherapy 2004, 48, 172-175.

Lamotte C, Landman R, Peytavin G, Mentre F, Gerbe J, Brun-Vezinet F, Boue F, Spiridon G, Valantin MA, Michelet C, Farinotti R, Yeni P
Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
Antiviral Therapy 2004, 9, 247-256.

2003


Camus M, Hennere G, Baron G, Peytavin G, Massias L, Mentre F, Farinotti R
Comparison of lithium concentrations in red blood cells and plasma in samples collected for TDM, acute toxicity, or acute-on-chronic toxicity.
European Journal of Clinical Pharmacology 2003, 59, 583-587.

2002


Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, Leport C, Peytavin G, Vilde JL
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
Antimicrobial Agents and Chemotherapy 2002, 46, 570-574.

2001


Mandelbrot L, Peytavin G, Firtion G, Farinotti R
Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women.
American Journal of Obstetrics and Gynecology 2001, 184, 153-158.

Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L
Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model.
American Journal of Obstetrics and Gynecology 2001, 185, 178-181.

2000


Duval X, Le Moing V, Longuet C, Leport C, Vildé JL, Lamotte C, Peytavin G, Farinotti R
Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir.
Antimicrobial Agents and Chemotherapy 2000, 44, 2593.

1999


Duval X, Peytavin G, Fouqueray B, Leport C, Vildé JL
Renin-angiotensin system inhibition in a patient having an overdose of HIV protease inhibitor.
AIDS (London, England) 1999, 13, 1983-1984.